argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia
(WorldNews Netherlands)

September 20, 2017 Top-line data from the study expected in second half of 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has recruited 50% of the immune thrombocytopenia (ITP) patients in the Phase 2 proof-of-concept study of ARGX-113. `We are pleased to have reached the 50% recruitment milestone in this study, which is enrolling on schedule,` commented Nicolas Leupin, Chief Medical Officer of argenx. `We remain on track, and look forward to presenting top-line data...